Signal transduction and transcription factors in rheumatic disease

Arthritis and Rheumatism

Volumn 42, Issue 4, 1999, Pages 609-621

  Firestein, Gary S ^a   Manning, Anthony M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR;

CELL TRANSFORMATION; ENZYME ACTIVATION; HUMAN; INFLAMMATION; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; RHEUMATIC DISEASES; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS;

EID: 0032931433     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199904)42:4<609::AID-ANR3>3.0.CO;2-I     Document Type: Review

References (126)

1. Karin M, Hunter T. Transcriptional control by protein phosphorylation: signal transmission from the cell surface to the nucleus. Curr Biol 1995;5:747-57.
2. Manning AM, Mercurio F. Transcription inhibitors in inflammation. Exp Opin Invest Drugs 1997;6:555-67.
3. Su B, Karin M. Mitogen-activated protein kinase cascades and the regulation of gene expression. Curr Opin Immunol 1996;8: 402-11.
4. Fanger GR, Gerwins P, Widmann C, Jarpe MB, Johnson GL. MEKKs, GCKs, MLKs, PAKs, TAKs, and Tpls: upstream regulators of the c-Jun amino-terminal kinases? Curr Opin Genet Dev 1997;7:67-74.
5. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell proliferation and transformation. Biochim Biophys Acta 1991;1072:129-57.
6. Kerppola TK, Curran T. Transcription factor interactions: basics on zippers. Curr Opin Struct Biol 1991;1:71-9.
7. Whitmarsh AJ, Davis RJ. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 1996;74:589-607.
8. Treisman Hill CS, Wynne J, Treisman R. The Rho family GTPases RhoA, Rac1 and CDC42Hs regulate transcriptional activation by SRF. Cell 1995;81:1159-70.
9. Angel P, Hattori K, Smeal T, Karin M. The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell 1988;55: 875-85.
10. Hibi M, Lin A, Smeal T, Minden A, Karin M. Identification of an oncoprotein and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 1993;7:2135-48.
11. Su B, Jacinto E, Hibi M, Kallunki T, Karin M, Ben-Neriah Y. JNK is involved in signal integration during co-stimulation of T lymphocytes. Cell 1994;77:727-36.
12. Kallunki T, Su B, Tsigelny I, Fries JW, Mori R, Maniwa S, et al. JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation. Genes Dev 1994;8: 2996-3007.
13. Hai T, Curran T. Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc Natl Acad Sci U S A 1991;88:3720-4.
14. Kaszubska W, Hooft van Huijsduijnen R, Ghersa P, DeRaemy-Schenk AM, Chen BP, Hai T, et al. Cyclic AMP-independent ATF family members interact with NF-κB and function in the activation of the E-selectin promoter in response to cytokines. Mol Cell Biol 1993;13:7180-90.
15. Tsai EY, Jain J, Pesavento PA, Rao A, Goldfeld AE. Tumor necrosis factor alpha gene regulation in activated T cell involves ATF-2/Jun and NFATp. Mol Cell Biol 1996;16:459-67.
16. Reimold AM, Grusby MJ, Kosaras B, Sluss HK, Derijard B, Moore G, et al. Chondrodysplasia and neurological abnormalities in ATF2-deficient mice. Nature 1996;379:262-5.
17. Gupta S, Campbell D, Derijard B, Davis RJ. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 1995;267:389-93.
18. Baeuerle PA, Henkel T. Function and activation of NF-κB in the immune system. Annu Rev Immunol 1994;12:141-79.
19. Baldwin AS. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-81.
20. Baeuerle PA, Baichwal VR. NF-κB as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol 1997;65:111-37.
21. Manning AM, Anderson DC. Transcription factor NF-κB: an emerging regulator of inflammation. Ann Rep Med Chem 1994; 29:235-44.
22. Hiscott J, Marois J, Garoufalis J, D'Addario M, Roulston A, Kwan I, et al. Characterization of a functional NF-κB site in the human interleukin 1β promoter: evidence for a positive autoregulatory loop. Mol Cell Biol 1993;13:6231-40.
23. Ziegler-Heitbrock HWL, Sternsdorf T, Liese T, Belohradsky B, Weber C, Wedel A, et al. Pyrrolidine dithiocarbamate inhibits NF-κB mobilization and TNF production in human monocytes. J Immunol 1993;151:6986-93.
24. Fujisawa K, Aono H, Hasunuma T, Yamamoto K, Mita S, Nishioka K. Activation of transcription factor NF-κB in human synovial cells in response to tumor necrosis factor α. Arthritis Rheum 1996;39:197-203.
25. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-κB and cytokine-inducible enhancers. FASEB J 1995; 9:899-909.
26. Chen CC, Rosenbloom CL, Anderson DC, Manning AM. Selective inhibition of E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 expression by inhibitors of IκB-α phosphorylation. J Immunol 1995;155:3538-45.
27. Kopp E, Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science 1994;265:956-9.
28. Yang JP, Merin JP, Nakano T, Kato T, Kitade Y, Okamoto T. Inhibition of the DNA-binding activity of NF-κB by gold compounds in vitro. FEBS Lett 1995;361:89-96.
29. Wahl C, Liptay S, Adler O, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998;101:1163-74.
30. Baeuerle PA, Baltimore D. NF-κB: ten years after. Cell 1996;87: 13-20.
31. Henkel T, Zabel U, van Zee K, Muller JM, Fanning E, Baeuerle P. Intramolecular masking of the nuclear location signal and dimerization domain in the precursor for the p50 NF-κB subunit. Cell 1992;68:1121-33.
32. Regnier CH, Song H, Gao H, Goeddel DV, Cao Z, Rothe M. Identification and characterization of an IκB kinase. Cell 1997; 90:373-83.
33. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine-responsive IκB kinase that activates the transcription factor NF-κB. Nature 1997;388:853-62.
34. Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li J, et al. IKK-1 and IKK-2: cytokine-activated IκB kinases essential for NF-κB activation. Science 1997;278:860-6.
35. Zandi E, Rothwarf DM, Delhasse M, Hayakawa M, Karin M. The IκB kinase complex (IKK) contains two kinase subunits, IKKa and IKKb, necessary for IκB phosphorylation and NF-κB activation. Cell 1997;91:243-52.
36. Yaron A, Alkalay I, Hatzubai A, Jung S, Beyth S, Mercurio F, et al. Inhibition of NF-κB cellular function via specific targeting of the IκB ubiquitin ligase. EMBO J 1997;16:101-7.
37. Alkalay I, Yaron A, Hatzubai A, Orian A, Ciechanover A, Ben-Neriah Y. Stimulation-dependent IκBα phosphorylation marks the NF-κB inhibitor for degradation via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 1995;92:10599-603.
38. Woronicz JD, Gao X, Cao Z, Rothe M, Goeddel DV. IκB kinase-α: NF-κB activation and complex formation with IκB kinase-α and NIK. Science 1997;278:866-9.
39. Lee FS, Hagler J, Chen ZJ, Maniatis T. Activation of the IκBα complex by MEKK1, a kinase of the JNK pathway. Cell 1997;88: 213-22.
40. Malinin NL, Boldin MP, Kovalenko AV, Wallach D. MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature 1997;385:540-4.
41. Nakano H, Shindo M, Sakon S, Nishinaka S, Mihara M, Yagita H, et al. Differential regulation of IκB kinase a and β by two upstream kinases, NF-κB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc Natl Acad Sci U S A 1998;95:3537-42.
42. Yin MJ, Christerson LB, Yamamoto Y, Kwak Y, Xu S, Mercurio F, et al. HTLV-1 tax protein binds to MEKK1 to stimulate IκB kinase activity and NF-κB activation. Cell 1998;93:875-84.
43. Zhong H, Voll RE, Ghosh S. Phosphorylation of NF-κB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1998;1:661-71.
44. Perkins ND, Felzien LK, Betts JC, Leung K, Beach DH, Nabel GJ. Regulation of NF-κB by cyclin-dependent kinases associated with the p300 coactivator. Science 1997;275:523-7.
45. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997;15: 707-47.
46. Shibasaki F, Price ER, Milan D, Mckeon F. Role of kinases and the phosphatase calcineurin in the nuclear shuttling of transcription factor NF-AT4. Nature 1996;382:370-3.
47. Shaw KTY, Ho AM, Raghavan A, Kim J, Jain J, Park J, et al. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci U S A 1995;92:11205-9.
48. Loh C, Shaw KT-Y, Carew J, Viola JPB, Luo C, Perrino BA, et al. Calcineurin binds the transcription factor NFAT1 and reversibly regulates its activity. J Biol Chem 1996;271:10884-91.
49. Jain J, Burgeon E, Badalian TM, Hogan PG, Rao A. A similar DNA-binding motif in NFAT family proteins and the rel homology region. J Biol Chem 1995;270:4138-45.
50. Kinoshita S, Su L, Amano M, Timmerman LA, Kaneshima H, Nolan GP. The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. Immunity 1997;6:235-44.
51. Jain J, McCaffrey PG, Miner Z, Kerppola TK, Lambert JN, Verdine GL, et al. The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature 1993;365:352-5.
52. Darnell J. STATs and gene regulation. Science 1997;277:1630-5.
53. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-induced inhibitors of signalling. Nature 1997;387:917-21.
54. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997;387:921-4.
55. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997;387:924-9.
56. Zhang X, Blenis J, Li HC, Schindler C, Chen-Kiang S. Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science 1996;267:1990-4.
57. Fields S, Jang SK. Presence of a potent transcription activating sequence in the p53 protein. Science 1990;249:1046-9.
58. Raycroft L, Wu HY, Lozano G. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 1990;249:1049-51.
59. Carrier F, Smith ML, Bae I, Kilpatrick KE, Lansing TJ, Chen CY, et al. Characterization of human Gadd45, a p53-regulated protein. J Biol Chem 1994;269:32672-7.
60. Buckbinder L, Talbott R, Seizinger BR, Kley N. Gene regulation by temperature-sensitive p53 mutants: identification of p53 response genes. Proc Natl Acad Sci U S A 1994;91:10640-4.
61. Shiio Y, Yamamoto T, Yamaguchi N. Negative regulation of Rb expression by the p53 gene product. Proc Natl Acad Sci U S A 1992;89:5206-10.
62. Smith ML, Chen IT, Zhan Q, Bae I, Chen CY, Gilmer TM, et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 1994;266:1376-80.
63. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993;8:307-18.
64. Ponten F, Berne B, Ren ZP, Nister M, Ponten J. Ultraviolet light induces expression of p53 and p21 in human skin: effect of sunscreen and constitutive p21 expression in skin appendages. J Invest Dermatol 1995;105:402-6.
65. Coates PJ, Save V, Ansari B, Hall PA. Demonstration of DNA damage/repair in individual cells using in situ end labelling: association of p53 with sites of DNA damage. J Pathol 1995;176: 19-26.
66. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88-91.
67. Hansson M, Asea A, Ersson U, Hermodsson S, Hellstrand K. Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J Immunol 1996;156:42-7.
68. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991;6:1699-703.
69. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 1992;151:237-44.
70. Firestein GS, Nguyen K, Aupperle K, Yeo M, Boyle DM, Zvaifler NJ. Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium. Am J Pathol 1996;149: 2143-51.
71. Didenko VV, Wang X, Yang L, Hornsby PJ. Expression of p21 (WAF1/CIP1/SDI1) and p53 in apoptotic cells in the adrenal cortex and induction by ischemia/reperfusion injury. J Clin Invest 1996;97:1723-31.
72. Soini Y, Kamel D, Paakko P, Lento VP, Oikarinen A, Vahakangas KV. Aberrant accumulation of p53 associates with Ki67 and mitotic count in benign skin lesions. Br J Dermatol 1994;131:514-20.
73. Ajioka Y, Watanahe H, Matsuda K. Over-expression of p53 protein in neoplastic changes in ulcerative colitis: immunohistochemical study. J Gastroenterol 1995;30 Suppl 8:33-5.
74. Ziegler A, Jonason AS, Leffell DJ. Simon JA, Sharma HW, Kimmelman J, et al. Sunburn and p53 in the onset of skin cancer. Nature 1994;372:773-6.
75. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
76. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-54.
77. Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985;162: 2163-8.
78. Kinne RW, Boehm S, Iftner T, Aigner T, Vornehm S, Weseloh G, et al. Synovial fibroblast-like cells strongly express jun-B and c-fos proto-oncogenes in rheumatoid and osteoarthritis. Scand J Rheumatol 1995;101 Suppl:121-5.
79. Trabandt A, Gay RE, Gay S. Oncogene activation in rheumatoid synovium. Apmis 1992;100:861-75.
80. Deleuran BW, Chu GQ, Field M, Brennan FM, Mitchell T, Feldmann M, et al. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis: implications for local actions of tumor necrosis factor α. Arthritis Rheum 1992;35:1170-8.
81. Asahara H, Fujisawa K, Kobata T, Hasunuma T, Maeda T, Asanuma M, et al. Direct evidence of high DNA binding activity of transcription factor AP-1 in rheumatoid arthritis synovium. Arthritis Rheum 1997;40:912-8.
82. Fujisawa K, Aono H, Hasunuma T, Yamamoto K, Mita S, Nishioka K. Activation of transcription factor NF-κB in human synovial cells in response to tumor necrosis factor α. Arthritis Rheum 1996;39:197-203.
83. Asahara H, Asanuma M, Ogawa N, Nishibayashi S, Inoue H. High DNA-binding activity of transcription factor NF-kappa B in synovial membranes of patients with rheumatoid arthritis. Biochem Mol Biol Int 1995;37:827-32.
84. Han Z, Boyle DL, Manning A, Firestein GS. AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 1998;28:197-208.
85. Alvaro-Gracia JM, Zvaifler NJ, Firestein GS. Cytokines in chronic inflammatory arthritis. V. Mutual antagonism between IFN-gamma and TNF-alpha on HLA-DR expression, proliferation, collagenase production, and GM-CSF production by rheumatoid arthritis synoviocytes. J Clin Invest 1990;86:1790-8.
86. Boyle DL, Han Z, Rutter JL, Brinckerhoff CE, Firestein GS. Posttranscriptional regulation of collagenase-1 gene expression in synoviocytes by adenosine receptor stimulation. Arthritis Rheum 1997;40:1772-9.
87. Wakisaka S, Suzuki N, Saito N, Ochi T, Sakane T. Possible correction of abnormal rheumatoid arthritis synovial cell function by jun D transfection in vitro. Arthritis Rheum 1998;41:470-81.
88. Okamoto K, Fujisawa K, Hasunuma T, Kobata T, Sumida T, Nishioka K. Selective activation of the JNK/AP-1 pathway in Fas-mediated apoptosis of rheumatoid arthritis synoviocytes. Arthritis Rheum 1997;40:919-26.
89. Han Z, Boyle DL, Bennett B, Aupperle KR, Manning AM, Firestein GS. Activation of Jun amino-terminal kinase in rheumatoid arthritis synoviocytes [abstract]. Arthritis Rheum 1998;41 Suppl 9:S136.
90. Geng Y, Valbracht J, Lotz M. Selective activation of the mitogen-activated protein kinase subgroups c-Jun NH2 terminal kinase and p38 by IL-1 and TNF in human articular chondrocytes. J Clin Invest 1996;98:2425-30.
91. Handel ML, McMorrow LB, Gravallese EM. Nuclear factor-κB in rheumatoid synovium: localization of p50 and p65. Arthritis Rheum 1995;38:1762-70.
92. Marok R, Winyard PG, Coumbe A, Kus ML, Gaffney K, Blades S, et al. Activation of the transcription factor nuclear factor-κB in human inflamed synovial tissue. Arthritis Rheum 1996;39:583-91.
93. Sioud M, Mellbye O, Forre O. Analysis of the NF-kappa B p65 subunit, Fas antigen, Fas ligand and Bcl-2-related proteins in the synovium of RA and polyarticular JRA. Clin Exp Rheumatol 1998;16:125-34.
94. Foxwell B, Browne K, Bondeson J, Clarke C, de Martin R, Brennan F, et al. Efficient adenoviral infection with IκB α reveals that macrophage tumor necrosis factor a production in rheumatoid arthritis is NF-κB dependent. Proc Natl Acad Sci U S A 1998;95:8211-5.
95. Liu R, O'Connell M, Johnson K, Pritzker K, Mackman N, Terkeltaub R. Activation of both NF-κB and MAP kinase ERK1/2 are essential for urate crystal and CPPD crystal-induced expression of the chemokine IL-8 in monocytes [abstract]. Arthritis Rheum 1998;41 Suppl 9:S358.
96. Aupperle KR, Bennett BL, Boyle DL, Tak PP, Manning AM, Firestein GS. Regulation of NF-κB by IκB kinase in fibroblast-like synoviocytes. J Immunol. In press.
97. Miyazawa K, Mori A, Yamamoto K, Okudaira H. Constitutive transcription of the human interleukin-6 gene by rheumatoid synoviocytes: spontaneous activation of NF-κB and CBF1. Am J Pathol 1998;152:793-803.
98. Miyazawa K, Mori A, Yamamoto K, Okudaira H. Transcriptional roles of CCAAT/enhancer binding protein-β, nuclear factor-κB, and C-promoter binding factor 1 in interleukin (IL)-1β-induced IL-6 synthesis by human rheumatoid fibroblast-like synoviocytes. J Biol Chem 1998;273:7620-7.
99. Tsao PW, Suzuki T, Totsuka R, Murata T, Takagi T, Ohmachi Y, et al. The effect of dexamethasone on the expression of activated NF-κ B in adjuvant arthritis. Clin Immunol Immunopathol 1997;83:173-8.
100. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, et al. Novel inhibitors of cytokine-induced IκBα phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 1997;272:21096-103.
101. Shiozawa S, Shimizu K, Tanaka K, Hino K. Studies on the contribution of c-fos/AP-1 to arthritic joint destruction. J Clin Invest 1997;99:1210-6.
102. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 1996;279:1453-61.
103. Jackson JR, Bolognese B, Hillegass L, Kassis S, Adams J, Griswold DE, et al. Pharmacological effects of SB 220025, a selective inhibitor of p38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J Pharmacol Exp Ther 1998;284:687-92.
104. Cato ACB, Wade E. Molecular mechanisms of anti-inflammatory action of glucocorticoids. Bioessays 1996;18:371-80.
105. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB-α synthesis. Science 1995;270: 286-90.
106. Scheinman RI, Crosswell PC, Loftquist AK, Baldwin AS. Role of transcriptional activation of NF-κB in mediation of the immunosuppression by glucocorticoids. Science 1995;270:283-6.
107. Nickels A, Selter H, Pfreundschuh M, Montenarh M, Koch B. Detection of p53 in inflammatory tissue and lymphocytes using immunohistory and flow cytometry: a critical comment. J Clin Pathol 1997;50:654-60.
108. Sugiyama M, Tsukazaki T, Yonekura A, Matsuzaki S, Yamashita S, Iwasaki K. Localisation of apoptosis and expression of apoptosis related proteins in the synovium of patients with rheumatoid arthritis. Ann Rheum Dis 1996;55:442-9.
109. Firestein GS, Echeverri F, Yeo M, Zvaifler NJ, Green DR. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A 1997;94:10895-900.
110. Reme T, Travaglio A, Gueydon E, Adla L, Jorgensen C, Sany J. Mutations of the p53 tumour suppressor gene in erosive rheumatoid synovial tissue. Clin Exp Immunol 1998;111:353-8.
111. Han Z, Boyle DL, Shi Y, Green D, Firestein GS. Dominant negative p53 mutations in rheumatoid arthritis. Arthritis Rheum. In press.
112. Harris CC. Deichmann lecture - p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology and cancer risk assessment. Toxicol Lett 1995;82-83:1-7.
113. Firestein GS. Invasive fibroblast-like synoviocytes in rheumatoid arthritis: passive responders or transformed aggressors? Arthritis Rheum 1996;39:1781-90.
114. Lafyatis R, Remmers EF, Roberts AB, Yocum DE, Sporn MB, Wilder RL. Anchorage-independent growth of synoviocytes from arthritic and normal joints: stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-β and retinoids. J Clin Invest 1989;83:1267-76.
115. Muller-Ladner U, Kriegsmann J, Franklin BN, Matsumoto S, Geiler T, Gay RE, et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 1996; 149:1607-15.
116. Aupperle K, Boyle DL, Hendrix M, Zvaifler NJ, Barbosa M, Firestein GS. Regulation of synoviocyte proliferation, apoptosis, and invasiveness by the p53 tumor suppressor gene. Am J Pathol 1998;152:1091-8.
117. Hu MC, Qiu WR, Wang YP. JNK1, JNK2 and JNK3 are p53 N-terminal serine 34 kinases. Oncogene 1997;15:2277-87.
118. Margulies L, Sehgal PB. Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBP β (NF-IL6) activity by p53 species. J Biol Chem 1993;268:15096-100.
119. Rayanade RJ, Ndubuisi MI, Etlinger JD, Sehgal PB. Regulation of IL-6 signaling by p53: STAT3-and STAT5-masking in p53-Vall35-containing human hepatoma Hep3B cell lines. J Immunol 1998;161:325-34.
120. Roivainen A, Soderstrom KO, Pirila L, Aro H, Kortekangas P, Merilahti-Palo R, et al. Oncoprotein expression in human synovial tissue: an immunohistochemical study of different types of arthritis. Br J Rheumatol 1996;35:933-42.
121. Roivainen A, Jalava J, Pirilä L, Yli-Jama T, Tiusanen H, Toivanen P. H-ras oncogene point mutations in arthritic synovium. Arthritis Rheum 1997;40:1636-43.
122. Montenarh M. Biochemical properties of the growth suppressor/ oncoprotein p53. Oncogene 1992;7:1673-80.
123. Wang F, Sengupta TK, Zhong Z, Ivashkiv LB. Regulation of the balance of cytokine production and the signal transducer and activator of transcription (STAT) transcription factor activity by cytokines and inflammatory synovial fluids. J Exp Med 1995;182: 1825-31.
124. Sengupta TK, Chen A, Zhong Z, Darnell JE, Ivashkiv LB. Activation of monocyte effector genes and STAT family transcription factors by inflammatory synovial fluid is independent of interferon. J Exp Med 1995;181:1015-25.
125. Thierfelder WE, van Deursen JM, Yamamoto K, Tripp RA, Sarawar SR, Carson RT, et al. Requirement for STAT4 in interleukin-12-mediated responses of natural killer and T cells. Nature 1996;382:171-4.
126. Shimoda K, van Deursen J, Sangster MY, Sarawar SR, Carson ST, Tripp RA, et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted STAT6 gene. Nature 1996;380:630-3.